Lista de obras - Sean Khozin - Dominio Público Uruguay

18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors

artículo científico publicado en 2013

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

artículo científico publicado en 2013

Advantages of a Truly Open-Access Data-Sharing Model

artículo científico publicado en 2017

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration

artículo científico publicado en 2015

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem.

artículo científico publicado en 2017

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval

artículo científico publicado en 2018

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

artículo científico publicado en 2014

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

artículo científico publicado en 2016

Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.

artículo científico publicado en 2013

Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period

artículo científico publicado en 2016

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

artículo científico publicado en 2015

Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement.

artículo científico publicado en 2012

INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology

scientific article published on 06 April 2018

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

artículo científico publicado en 2002

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis

artículo científico

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

artículo científico publicado en 2016

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses

artículo científico publicado en 2015

Real-world Data for Clinical Evidence Generation in Oncology

artículo científico publicado en 2017

Regulatory watch: Evaluating the potential for digital submission of expedited premarket safety reports to the FDA.

artículo científico publicado en 2016

Regulatory watch: From big data to smart data: FDA's INFORMED initiative

artículo científico publicado en 2017

Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?

artículo científico publicado en 2015

Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.

artículo científico publicado en 2012

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

artículo científico publicado en 2016

The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative

artículo científico publicado en 2016

The effects of adrenalectomy and aldosterone replacement in transgenic mice expressing antisense RNA to the type 2 glucocorticoid receptor.

artículo científico publicado en 2002

U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.

artículo científico publicado en 2017

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

artículo científico publicado en 2014

Using the hierarchy of control technologies to improve healthcare facility infection control: lessons from severe acute respiratory syndrome.

artículo científico publicado en 2004

Lista de obras de Sean Khozin

18F-fluorodeoxyglucose positron emission tomography in the management of patients with thymic epithelial tumors

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

Advantages of a Truly Open-Access Data-Sharing Model

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem.

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval

Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial

Clinician Perspectives on Current Issues in Lung Cancer Drug Development.

Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations.

Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

Hepatoid carcinoma of the lung with anaplastic lymphoma kinase gene rearrangement.

INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology

Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects

Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses

Real-world Data for Clinical Evidence Generation in Oncology

Regulatory watch: Evaluating the potential for digital submission of expedited premarket safety reports to the FDA.

Regulatory watch: From big data to smart data: FDA's INFORMED initiative

Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?

Response to crizotinib in ROS1-rearranged non-small-cell lung cancer.

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative

The effects of adrenalectomy and aldosterone replacement in transgenic mice expressing antisense RNA to the type 2 glucocorticoid receptor.

U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

Using the hierarchy of control technologies to improve healthcare facility infection control: lessons from severe acute respiratory syndrome.